<DOC>
	<DOCNO>NCT01677507</DOCNO>
	<brief_summary>Glaucoma major cause blindness . The inability predict patient 's IOP response medication critical barrier clinician consistently provide highly effective IOP-based treatment . Current trial-and error approach glaucoma management inefficient address barrier predictive factor drug response . Our long-term goal improve outcome identify biomarkers environmental factor profile patient risk glaucoma age-of-onset , rate disease progression , `` poor response '' treatment , large IOP fluctuation . Our purpose research project address critical barrier focus physiological factor predict IOP response drug .</brief_summary>
	<brief_title>Glaucoma Biomarkers</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Either gender . Any selfdeclared ethnoracial category . Greater equal 40 year . Healthy eye crystalline lens , without glaucoma ( cup : disc ratio &lt; 0.8 eye ; asymmetry cup : disc ratio eye &lt; 0.2 ) . Open angle . Ability cooperate aqueous humor dynamic study . Nonprescription prescription topical ophthalmic product systemic medication mention exclusion criterion allow study . Contact lenses remove prior topical fluorescein instillation , use end fluorophotometry session . Able participate site multivisit study period . Women pregnant due IOP change . Any form glaucoma , include extremely narrow angle complete partial closure . Current use glaucoma medication , either topically orally . Chronic recurrent inflammatory eye disease . Ocular trauma within past 6 month . Ocular infection ocular inflammation past 3 month . Clinically significant retinal disease . Any abnormality prevent reliable fluorophotometry either eye , corneal scar severe dry eye result punctate fluorescein stain cornea . Intraocular surgery within 6 month . Serious hypersensitivity component study medication risk treatment glaucoma medication , severe asthma emphysema . Subjects must stable regimen least 30 day prior Visit 1 regard chronic systemic medication may affect IOP ( i.e. , sympathomimetic agent , betablockers , alphaadrenergic agonist , alphaadrenergic blocker , calcium channel blocker , angiotensin convert enzyme inhibitor , etc. ) . Any change medication study period result exclusion . Use glucocorticoid route . Subject must wash glucocorticoid least 2 week study entry .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>glaucoma</keyword>
	<keyword>aqueous humor dynamic</keyword>
	<keyword>intraocular pressure</keyword>
</DOC>